These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 25660252

  • 21. Treatment for older men with fractures.
    Shepherd AJ, Cass AR, Ray LA, Tan A, Wilkinson GS.
    Osteoporos Int; 2012 Mar; 23(3):1041-51. PubMed ID: 21811867
    [Abstract] [Full Text] [Related]

  • 22. Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.
    Naranjo A, Fernández-Conde S, Ojeda S, Torres-Hernández L, Hernández-Carballo C, Bernardos I, Rodríguez S, Laynez P.
    Arch Osteoporos; 2017 Dec 11; 12(1):112. PubMed ID: 29230540
    [Abstract] [Full Text] [Related]

  • 23. Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study.
    Shah A, Prieto-Alhambra D, Hawley S, Delmestri A, Lippett J, Cooper C, Judge A, Javaid MK, REFReSH study team.
    Osteoporos Int; 2017 Jan 11; 28(1):169-178. PubMed ID: 27812809
    [Abstract] [Full Text] [Related]

  • 24. Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study.
    García-Sempere A, Hurtado I, Sanfélix-Genovés J, Rodríguez-Bernal CL, Gil Orozco R, Peiró S, Sanfélix-Gimeno G.
    Sci Rep; 2017 Sep 18; 7(1):11784. PubMed ID: 28924156
    [Abstract] [Full Text] [Related]

  • 25. Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore.
    Chau YT, Nashi N, Law LS, Goh RKH, Choo SX, Seetharaman SK.
    Arch Osteoporos; 2020 Sep 11; 15(1):141. PubMed ID: 32918196
    [Abstract] [Full Text] [Related]

  • 26. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
    Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O'Malley CD.
    J Bone Joint Surg Am; 2014 Apr 02; 96(7):e52. PubMed ID: 24695929
    [Abstract] [Full Text] [Related]

  • 27. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
    Wilk A, Sajjan S, Modi A, Fan CP, Mavros P.
    Osteoporos Int; 2014 Dec 02; 25(12):2777-86. PubMed ID: 25112720
    [Abstract] [Full Text] [Related]

  • 28. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Möller G, Kalouche-Khalil L, Fahrleitner-Pammer A.
    Osteoporos Int; 2015 Oct 02; 26(10):2479-89. PubMed ID: 26018090
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Two-year adherence to treatment and associated factors in a fracture liaison service in Spain.
    Naranjo A, Ojeda-Bruno S, Bilbao-Cantarero A, Quevedo-Abeledo JC, Diaz-González BV, Rodríguez-Lozano C.
    Osteoporos Int; 2015 Nov 02; 26(11):2579-85. PubMed ID: 26048675
    [Abstract] [Full Text] [Related]

  • 31. Patients' first-year adherence to different anti-osteoporotic therapy after hip fractures.
    Kim SJ, Cho YJ, Lee DW.
    Injury; 2021 Jun 02; 52(6):1506-1510. PubMed ID: 33223260
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
    Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E.
    Osteoporos Int; 2016 Jan 02; 27(1):387-96. PubMed ID: 26576544
    [Abstract] [Full Text] [Related]

  • 35. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S.
    Mayo Clin Proc; 2006 Aug 02; 81(8):1013-22. PubMed ID: 16901023
    [Abstract] [Full Text] [Related]

  • 36. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, Huang KE.
    Osteoporos Int; 2013 Feb 02; 24(2):511-21. PubMed ID: 22588182
    [Abstract] [Full Text] [Related]

  • 37. Hip fracture trends in the United States, 2002 to 2015.
    Lewiecki EM, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, Singer AJ, Steven PM, Adler RA.
    Osteoporos Int; 2018 Mar 02; 29(3):717-722. PubMed ID: 29282482
    [Abstract] [Full Text] [Related]

  • 38. Trends in hospital care for hip fractures.
    Gehlbach SH, Avrunin JS, Puleo E.
    Osteoporos Int; 2007 May 02; 18(5):585-91. PubMed ID: 17146592
    [Abstract] [Full Text] [Related]

  • 39. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race.
    Antonelli M, Einstadter D, Magrey M.
    J Clin Densitom; 2014 May 02; 17(4):479-83. PubMed ID: 24657109
    [Abstract] [Full Text] [Related]

  • 40. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
    Hansen L, Petersen KD, Eriksen SA, Gerstoft F, Vestergaard P.
    Osteoporos Int; 2017 Jan 02; 28(1):321-328. PubMed ID: 27475930
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.